دورية أكاديمية
أعرض في EDS

Does neoadjuvant therapy for pancreatic head adenocarcinoma increase postoperative morbidity? A systematic review of the literature with meta-analysis.

التفاصيل البيبلوغرافية
العنوان: Does neoadjuvant therapy for pancreatic head adenocarcinoma increase postoperative morbidity? A systematic review of the literature with meta-analysis.
المؤلفون: Araujo RLC; Department of Digestive Surgery, Escola Paulista de Medicina (UNIFESP), São Paulo, São Paulo, Brazil.; Post-graduation Program, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.; Department of Oncology, Hospital Israelita Albert Einstein, São Paulo, São Paulo, Brazil., Silva RO; Department of Surgical Oncology, Hospital Santa Casa, Campo Mourão, Paraná, Brazil., de Pádua Souza C; Post-graduation Program, Barretos Cancer Hospital, Barretos, São Paulo, Brazil., Milani JM; Post-graduation Program, Barretos Cancer Hospital, Barretos, São Paulo, Brazil., Huguet F; Department of Radiation Oncology, Hôpital Tenon AP-HP, Sorbonne University, Paris, France., Rezende AC; Department of Oncology, Hospital Israelita Albert Einstein, São Paulo, São Paulo, Brazil., Gaujoux S; Department of Digestive, Pancreatic and Endocrine Surgery, Hôpital Cochin AP-HP, Paris, France.
المصدر: Journal of surgical oncology [J Surg Oncol] 2020 Apr; Vol. 121 (5), pp. 881-892. Date of Electronic Publication: 2020 Jan 28.
نوع المنشور: Journal Article; Meta-Analysis; Systematic Review
اللغة: English
بيانات الدورية: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 0222643 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-9098 (Electronic) Linking ISSN: 00224790 NLM ISO Abbreviation: J Surg Oncol Subsets: MEDLINE
أسماء مطبوعة: Publication: <2005-> : Hoboken, NJ : Wiley-Liss
Original Publication: New York, Plenum.
مواضيع طبية MeSH: Neoadjuvant Therapy* , Postoperative Complications*, Adenocarcinoma/*therapy , Pancreatic Neoplasms/*therapy, Adenocarcinoma/mortality ; Adenocarcinoma/pathology ; Chemotherapy, Adjuvant ; Humans ; Pancreatic Fistula/etiology ; Pancreatic Neoplasms/mortality ; Pancreatic Neoplasms/pathology ; Radiotherapy, Adjuvant
مستخلص: Neoadjuvant treatment (NT) for pancreatic head cancer may allow some patients to undergo curative resection, but its impact on postoperative complications remains unclear. A systematic review and meta-analysis were performed to compare overall postoperative morbidity, pancreatic fistula, and mortality between patients who underwent upfront surgery and those who underwent neoadjuvant therapy first. Forty-five studies with 3359 patients were included. No significant differences in morbidity and mortality rates associated with NT for pancreatic head cancer were detected in this study.
(© 2020 Wiley Periodicals, Inc.)
References: Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7-30.
Bickenbach KA, Gonen M, Tang LH, et al. Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease. Ann Surg Oncol. 2012;19(5):1663-1669.
Araujo RLC, Karkar AM, Allen PJ, et al. Timing of elective surgery as a perioperative outcome variable: analysis of pancreaticoduodenectomy. HPB. 2014;16(3):250-262.
Crist DW, Sitzmann JV, Cameron JL. Improved hospital morbidity, mortality, and survival after the Whipple procedure. Ann Surg. 1987;206(3):358-365.
Kawai M, Yamaue H. Analysis of clinical trials evaluating complications after pancreaticoduodenectomy: a new era of pancreatic surgery. Surg Today. 2010;40(11):1011-1017.
Pellegrini CA, Heck CF, Raper S, Way LW. An analysis of the reduced morbidity and mortality rates after pancreaticoduodenectomy. Arch Surg. 1989;124(7):778-781.
Yeo CJ, Cameron JL, Sohn TA, et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg. 1997;226(3):248-257.
Bilimoria KY, Talamonti MS, Sener SF, et al. Effect of hospital volume on margin status after pancreaticoduodenectomy for cancer. J Am Coll Surg. 2008;207(4):510-519.
Birkmeyer JD, Siewers AE, Finlayson EVA, et al. Hospital volume and surgical mortality in the United States. N Engl J Med. 2002;346(15):1128-1137.
Birkmeyer JD, Warshaw AL, Finlayson SR, Grove MR, Tosteson AN. Relationship between hospital volume and late survival after pancreaticoduodenectomy. Surgery. 1999;126(2):178-183.
Kalser MH, Barkin J, MacIntyre JM. Pancreatic cancer. Assessment of prognosis by clinical presentation. Cancer. 1985;56(2):397-402.
Porta M, Fabregat X, Malats N, et al. Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage. Clin Transl Oncol. 2005;7(5):189-197.
Evans DB, Varadhachary GR, Crane CH, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26(21):3496-3502.
Joensuu TK, Kiviluoto T, Kärkkäinen P, et al. Phase I-II trial of twice-weekly gemcitabine and concomitant irradiation in patients undergoing pancreaticoduodenectomy with extended lymphadenectomy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2004;60(2):444-452.
Talamonti MS, Small W Jr, Mulcahy MF, et al. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol. 2006;13(2):150-158.
Varadhachary GR, Wolff RA, Crane CH, et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26(21):3487-3495.
Conroy T, Paillot B, François E, et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer-a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. J Clin Oncol. 2005;23(6):1228-1236.
Liberati A. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):W65-W94.
Mavridis D, Salanti G. Exploring and accounting for publication bias in mental health: a brief overview of methods. Evid Based Ment Health. 2014;17(1):11-15.
Mavridis D, Salanti G. How to assess publication bias: funnel plot, trim-and-fill method and selection models. Evid Based Ment Health. 2014;17(1):30.
Nyaga VN, Arbyn M, Aerts M. Metaprop: a Stata command to perform meta-analysis of binomial data. Arch Public Health. 2014;72(1):39.
Freeman MF, Turkey JW. Transformations related to the angular and the square root. Ann Math Stats. 1950;21(4):404-413.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials. 1986;7(3):177-188.
Paye F, Micelli Lupinacci R, Bachellier P, Boher JM, Delpero JR. Distal pancreatectomy for pancreatic carcinoma in the era of multimodal treatment. Br J Surg. 2015;102(3):229-236.
Sata N, Kurashina K, Nagai H, et al. The effect of adjuvant and neoadjuvant chemo(radio)therapy on survival in 1,679 resected pancreatic carcinoma cases in Japan: report of the national survey in the 34th annual meeting of Japanese Society of Pancreatic Surgery. J Hepatobiliary Pancreat Surg. 2009;16(4):485-492.
White R, Lee C, Anscher M, et al. Preoperative chemoradiation for patients with locally advanced adenocarcinoma of the pancreas. Ann Surg Oncol. 1999;6(1):38-45.
Weese JL, Nussbaum ML, Paul AR, et al. Increased resectability of locally advanced pancreatic and periampullary carcinoma with neoadjuvant chemoradiotherapy. Int J Pancreatol. 1990;7(1-3):177-185.
Chao C, Hoffman JP, Ross EA, Torosian MH, Eisenberg BL. Pancreatic carcinoma deemed unresectable at exploration may be resected for cure: an institutional experience. Am Surg. 2000;66(4):378-385. discussion 86.
Cheng TY, Sheth K, White RR, et al. Effect of neoadjuvant chemoradiation on operative mortality and morbidity for pancreaticoduodenectomy. Ann Surg Oncol. 2006;13(1):66-74.
Vento P, Mustonen H, Joensuu T, Karkkainen P, Kivilaakso E, Kiviluoto T. Impact of preoperative chemoradiotherapy on survival in patients with resectable pancreatic cancer. World J Gastroenterol. 2007;13(21):2945-2951.
Allendorf JD, Lauerman M, Bill A, et al. Neoadjuvant chemotherapy and radiation for patients with locally unresectable pancreatic adenocarcinoma: feasibility, efficacy, and survival. J Gastrointest Surg. 2008;12(1):91-100.
Barbier L, Turrini O, Gregoire E, Viret F, Le Treut YP, Delpero JR. Pancreatic head resectable adenocarcinoma: preoperative chemoradiation improves local control but does not affect survival. HPB. 2011;13(1):64-69.
Barugola G, Partelli S, Crippa S, et al. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy. Am J Surg. 2012;203(2):132-139.
Araujo RLC, Gaujoux S, Huguet F, et al. Does pre-operative chemoradiation for initially unresectable or borderline resectable pancreatic adenocarcinoma increase post-operative morbidity? A case-matched analysis. HPB. 2013;15(8):574-580.
Cho IR, Chung MJ, Bang S, et al. Gemcitabine based neoadjuvant chemoradiotherapy therapy in patients with borderline resectable pancreatic cancer. Pancreatology. 2013;13(5):539-543.
Denost Q, Laurent C, Adam JP, et al. Pancreaticoduodenectomy following chemoradiotherapy for locally advanced adenocarcinoma of the pancreatic head. HPB. 2013;15(9):716-723.
Jiang H, Du C, Cai M, et al. An evaluation of neoadjuvant chemoradiotherapy for patients with resectable pancreatic ductal adenocarcinoma. HPB Surg. 2013;2013:298726.
Fujii T, Yamada S, Murotani K, et al. Inverse probability of treatment weighting analysis of upfront surgery versus neoadjuvant chemoradiotherapy followed by surgery for pancreatic adenocarcinoma with arterial abutment. Medicine. 2015;94(39):1-9.
Casadei R, Di Marco M, Ricci C, et al. Neoadjuvant chemoradiotherapy and surgery versus surgery alone in resectable pancreatic cancer: a single-center prospective, randomized, controlled trial which failed to achieve accrual targets. J Gastrointest Surg. 2015;19(10):1802-1812.
Golcher H, Brunner TB, Witzigmann H, et al. Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial. Strahlenther Onkol. 2015;191(1):7-16.
Lee JH, Kang CM, Bang SM, et al. The role of neoadjuvant chemoradiation therapy in patients with borderline resectable pancreatic cancer with isolated venous vascular involvement. Medicine. 2015;94(31):1-9.
Sho M, Akahori T, Tanaka T, et al. Optimal indication of neoadjuvant chemoradiotherapy for pancreatic cancer. Langenbecks Arch Surg. 2015;400(4):477-485.
Mellon EA, Strom TJ, Hoffe SE, et al. Favorable perioperative outcomes after resection of borderline resectable pancreatic cancer treated with neoadjuvant stereotactic radiation and chemotherapy compared with upfront pancreatectomy for resectable cancer. J Gastrointest Oncol. 2016;7(4):547-555.
Hoffman JP, Weese JL, Solin LJ, et al. A pilot study of preoperative chemoradiation for patients with localized adenocarcinoma of the pancreas. Am J Surg. 1995;169(1):71-77.
Bousquet J, Slim K, Pezet D, et al. [Does neoadjuvant radiochemotherapy augment the resectability of pancreatic cancers?]. Chirurgie. 1998;123(5):456-460.
White RR, Hurwitz HI, Morse MA, et al. Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Ann Surg Oncol. 2001;8(10):758-765.
Gerke H, White R, Byrne MF, et al. Complications of pancreaticoduodenectomy after neoadjuvant chemoradiation in patients with and without preoperative biliary drainage. Dig Liver Dis. 2004;36(6):412-418.
White RR, Tyler DS. Neoadjuvant therapy for pancreatic cancer: the Duke experience. Surg Oncol Clin N Am. 2004;13(4):675-684.
Delpero JR, Turrini O. [Locally advanced pancreatic adenocarcinoma. Chemoradiotherapy, reevaluation and secondary resection]. Cancer Radiother. 2006;10(6-7):462-470.
Massucco P, Capussotti L, Magnino A, et al. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival. Ann Surg Oncol. 2006;13(9):1201-1208.
Turrini O, Moutardier V, Guiramand J, Viret F, Giovaninni M, Delpero JR. Long term morbidity of neoadjuvant chemoradiation for pancreatic head adenocarcinoma. Eur J Surg Oncol. 2006;32(1):77-79.
Brown KM, Siripurapu V, Davidson M, et al. Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma. Am J Surg. 2008;195(3):318-321.
Lind PA, Isaksson B, Almström M, et al. Efficacy of preoperative radiochemotherapy in patients with locally advanced pancreatic carcinoma. Acta Oncol. 2008;47(3):413-420.
Turrini O, Viret F, Moureau-Zabotto L, et al. Neoadjuvant chemoradiation and pancreaticoduodenectomy for initially locally advanced head pancreatic adenocarcinoma. Eur J Surg Oncol. 2009;35(12):1306-1311.
Turrini O, Ychou M, Moureau-Zabotto L, et al. Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: new neoadjuvant regimen was safe and provided an interesting pathologic response. Eur J Surg Oncol. 2010;36(10):987-992.
Lee JL, Kim SC, Kim JH, et al. Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma. Surgery. 2012;152(5):851-862.
Satoi S, Toyokawa H, Yanagimoto H, et al. Neo-adjuvant chemoradiation therapy using S-1 followed by surgical resection in patients with pancreatic cancer. J Gastrointest Surg. 2012;16(4):784-792.
Strobel O, Berens V, Hinz U, et al. Resection after neoadjuvant therapy for locally advanced, "unresectable" pancreatic cancer. Surgery. 2012;152(3 suppl 1):S33-S42.
Motoi F, Ishida K, Fujishima F, et al. Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial. Ann Surg Oncol. 2013;20(12):3794-3801.
Addeo P, Rosso E, Fuchshuber P, et al. Resection of borderline resectable and locally advanced pancreatic adenocarcinomas after neoadjuvant chemotherapy. Oncology. 2015;89(1):37-46.
Kharofa J, Tsai S, Kelly T, et al. Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer. Radiother Oncol. 2014;113(1):41-46.
Opendro SS, Satoi S, Yanagimoto H, et al. Role of adjuvant surgery in initially unresectable pancreatic cancer after long-term chemotherapy or chemoradiation therapy: survival benefit? J Hepatobiliary Pancreat Sci. 2014;21(9):695-702.
Rose JB, Rocha FG, Alseidi A, et al. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival. Ann Surg Oncol. 2014;21(5):1530-1537.
Amano R, Kimura K, Nakata B, et al. Pancreatectomy with major arterial resection after neoadjuvant chemoradiotherapy gemcitabine and S-1 and concurrent radiotherapy for locally advanced unresectable pancreatic cancer. Surgery. 2015;158(1):191-200.
Nanda RH, El-Rayes B, Maithel SK, Landry J. Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability. J Surg Oncol. 2015;111(8):1028-1034.
Sherman WH, Chu K, Chabot J, et al. Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy and surgery in locally advanced, unresectable pancreatic adenocarcinoma. Cancer. 2015;121(5):673-680.
Tomimaru Y, Eguchi H, Satoh T, et al. Feasibility of pre-operative chemoradiotherapy with gemcitabine to treat pancreatic cancer in patients with impaired renal function. Jpn J Clin Oncol. 2015;45(4):343-348.
Christians KK, Heimler JW, George B, et al. Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy. Surgery. 2016;159(3):893-900.
Denbo JW, Bruno ML, Cloyd JM, et al. Preoperative chemoradiation for pancreatic adenocarcinoma does not increase 90-day postoperative morbidity or mortality. J Gastrointest Surg. 2016;20(12):1975-1985.
Bravata DM, Olkin I. Simple pooling versus combining in meta-analysis. Eval Health Prof. 2001;24(2):218-230.
Orr RK. Outcomes in pancreatic cancer surgery. Surg Clin North Am. 2010;90(2):219-234.
Andriulli A, Festa V, Botteri E, et al. Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies. Ann Surg Oncol. 2012;19(5):1644-1662.
Assifi MM, Lu X, Eibl G, Reber HA, Li G, Hines OJ. Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. Surgery. 2011;150(3):466-473.
Gillen S, Schuster T, Meyer Zum Buschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7(4):1-15.
Hajj CH, Wu F, Wu AJC, et al. Intensity-modulated radiation therapy (IMRT) in patients with locally advanced pancreatic cancer (LAPC). J Clin Oncol. 2015;33(suppl 3):377.
Versteijne E, van Eijck CHJ, Punt CJA, et al. Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial. Trials. 2016;17(1):127.
Varadhachary GR, Tamm EP, Abbruzzese JL, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006;13(8):1035-1046.
National Comprehensive Cancer Network. Pancreatic Adenocarcinoma. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). 2019.
Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205-213.
Bassi C, Dervenis C, Butturini G, et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery. 2005;138(1):8-13.
فهرسة مساهمة: Keywords: chemoradiotherapy; chemotherapy; morbidity; neoadjuvant treatment; pancreatic cancer; radiotherapy
تواريخ الأحداث: Date Created: 20200130 Date Completed: 20200323 Latest Revision: 20200323
رمز التحديث: 20221213
DOI: 10.1002/jso.25851
PMID: 31994193
قاعدة البيانات: MEDLINE
الوصف
تدمد:1096-9098
DOI:10.1002/jso.25851